Clinical trials: Vaping Cessation
Smoking Cessation
Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette.
- Trial name
- BuZonE (NCT04388319)
- Testing
- Zonisamide, Bupropion, Halo G6 e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked.
- Conditions
- Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking
- Trial name
- RECON (NCT04188197)
- Testing
- JUUL
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation
Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes
The purpose of this study is to develop and pilot test an enhanced behavioral coaching intervention for dual users of cigarettes and electronic nicotine delivery systems (ENDS) who call tobacco quitlines for help quitting smoking.
- Trial name
- NCT03575468
- Testing
- Enhanced E-cigarette Coaching, Quitline treatment as usual
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Vaping, E-Cig Use
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
- Trial name
- ORCA-V1 (NCT05431387)
- Testing
- cytisinicline, Behavioral support
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Achieve Life Sciences